Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very excited that Oncosec is holding up so well. With good news at AACR and PISCES data later this year we are primed to fly higher.
Very strong close today for Oncosec in a very negative day for the rest of the market.
Oncosec looking to close the day Strong and Green, currently 1.95.
Oncosec up 5% so far today and heading back to $2. Nice!
Accumulation in Oncosec shares continues today in anticipation of AACR presentation in 2 weeks. Abstract is currently embargoed.....so expecting exciting news.
Oncosec shares rising! BMY collaboration possibly with cash money coming to Oncosec. Just speculation at this point, but very good possibility.
Go Oncosec! AACR coming soon with great developments to share!
Hey, no problem. No worries, we all know Oncosec has great times ahead...and that is totally backed up by positive data and excellent science. GLTA!
Ha Ha Ha....good one. I also know where Oncosec is headed. LOL!....UP.
LOL...okay, just giving you a heads up Bro!
Ha Ha...LOL...just giving you the heads up so you don't forget.
Oncosec will very likely pick up more reputable analyst coverage further into 2018.
Sell side or buy side analyst targets will not make much difference in my opinion if Oncosec gets PISCES trial fast track approval. Peak sales of 500 million in melanoma alone will certainly lead to a much higher share price.....likely to dwarf current price targets in the $4-$6 range. A second future approval for Oncosec in TNBC might double their overall peak revenue numbers to 1 Billion. I think Big Pharma would lick their chops for a piece of that.
Here is a link which provides information about buyside and sellside analysts jobs and key differences/similarities:
https://www.investopedia.com/articles/financialcareers/11/sell-side-buy-side-analysts.asp
Charles Duncan for Piper Jaffray seems reputable to me even if his Oncosec price target is below the rest at $4. That is still more than double the current stock price. http://www.piperjaffray.com/2col.aspx?id=7&analystid=1275&title=Analyst%20Information%20for%20Charles%20Duncan,%20PhD
In two weeks we will know more regarding TNBC plans when AACR happens. Next few months will reveal just how compelling Oncosec valuation is to Big Pharma. PISCES for melanoma and TNBC are the current value drivers. If all is positive in the near-term we will see Oncosec hitting the conservative price targets of $5 to $6. Longer-term can't be determined yet regarding multi-gene construct. I believe PISCES and TNBC positive news would be enough to trigger a buyout or major licensing deals at this point though. Licensing deals with major cash and the share price would move higher than the current price targets. Positive trial news with no licensing deal or buyout and we will see a pop and drop with the share price....and more equity raises to fund trials. Upfront money or buyout is the hope here.
haha...sure....okay....we will see in a few months just how interested BP is after more news and data hits.....I think the interest will certainly increase on good news.
The writing is on the wall. Big Pharma and Bio are realizing they need to jump in earlier in the game, earlier stage development to lock in potential therapies that will create new revenues down the line. Example: Jounce and Celgene have an extensive licensing deal...and probably years from commercialization. Oncosec is only months away from data leading to a possible fast track approval in melanoma....2019....and hitting the market shortly after. What small bio can say that right now. PISCES alone is enough to secure a buyout. Years and years of positive data brushed off by the market until now.
Nice to see the volume has been strongly on the buy side for days now. We just may see some filings next week.
Only weak hands selling Oncosec Medical now. Strength in daily volume and chart are undeniable in anticipation of TNBC news and PISCES trial data.
And I guess Merck could care less about their collaboration with Oncosec and PISCES trial, just like they didn't care at all about their collaboration with Viralytics either....oh wait....they just bought out Viralytics.....even before anticipated data release.
like it or not, alot of people are watching Oncosec and anticipating great PISCES data.
As stated in the past Oncosec sees an exit opportunity with PISCES data release. If the news is good I do believe they get a buyout offer from Merck. At this point does Oncosec accept an offer. With the possibility to expand the pipeline and grow organically...TNBC news from AACR will shed more light on things. Maybe they decide to stick with licensing or maybe a buyout offer will be much higher than expected and too good to pass up.
Also a licensing deal for their multi-gene construct with another Big Pharma or Biotech company is also very likely.
I licensing deal with Merck is very likely for malanoma after PISCES....and a licensing deal with Bristol Myers for TNBC is also very likely.
After Hours buying is pushing the price to 1.95 now....close to 2 bucks again.....hmmmm. a pr reales in the morning maybe?
I don't think Merck is buying shares of Oncosec on the open market. If they were or are interested in taking a stake in Oncosec we would or will see the proper 13D or 13G filing soon. As for the current share price I do believe TNBC news will drive the price above $2 soon and keep it there until PISCES data is released. If Oncosec does get any buyout offers I think it will happen after positive readout in PISCES trial.
Nice close today...GREEN...1.91
More likely to see a pr after PISCES data release that Merck ia acquiring Oncosec completely rather than a 13d for a partial stake in the company....that would be peanuts
no, not 10 cents my friend....currently 1.88 and that is a fair price before data reveal of PISCES data. Good results and a fair price for Oncosec shares will dwarf 1.88.....going much higher here.....TNBC only sweetens the deal while we wait for PISCES data.
No, not the next Apple, we are talking Biotech....the next Nektar!
Any smart investor would have their eyes on a ground-breaking company trading for under $2. Even genius investors don't always see the light until it costs hundreds of dollars when they could have bought for a few bucks before the market caught on. Example: APPLE
Either Oncosec found 2 needles in a haystack or the combination of ep-il12 plus Opdivo is a highly effective treatment in TNBC, an extremely hard to treat patient population.
Actually TNBC has an extremely low response rate even with checkpoint therapy so the Oncosec therapy of ep-il12 seems to be priming the immune sytstem for a robsut response to Opdivo. That is why the Oncosec abstract for AACR is currently embargoed....it is very exciting news and is the reason why Oncosec is planning to speed ahead with a phase II combo study for TNBC following the AACR conference. They are holding a special meeting to reveal their plans after the abstract presentation.
Yes the pilot TNBC study was intended to enroll 10 patients (only 5 total enrolled) and was very slow going. The investigator at Stanford initiated the dosing of patient #4 and #5 with Opdivo after the ep-il12 monotherapy after hearing the encouraging data from Oncosec's combo study with Merck in melanoma (checkpoint therapy) was revealed. So far Oncosec has said these 2 patients experienced a robust response. These 2 patients previously failed other treatments.
The excitement about these 2 patients is this:
1) They were dosed with Opdivo and both patients had a robust response...even though that is only 2 patients that is a 100% response rate. Was it dumb luck that both patients responded or is it predictive of a very effective therapy in a very hard to treat patient population. TNBC has a very low response rate with current therapies.
2) With the dosing of Opdivo instead of Keytruda in this study....Bristol Myers now enters the picture
3) The market was not even really expecting any real earth shattering news from the TNBC pilot study. My feeling was that it was being shelved until these 2 patients were dosed with Opdivo. A phase II combo study was not expected ...at least this quickly. (23 million equity offering recently was done to fund this future trial) Oncosec plans to get this trial going quickly after AACR.
4) PISCES data soon plus TNBC sweetens investor interest this year because M&A in biotech will continue (small biotech like Viralytics are being bought out and Oncosec might be next)
5) TNBC news is giving investors more to think about when condisering Oncosec as an investment...it's not just a one trick pony with melanoma approval on the horizon.
Oncosec hit 2.03 before pulling back today in a terrible market. Momentum is growing in anticipation of AACR TNBC embargoed abstract reveal.....also special meeting about anticipated TNBC phase II trial information....all leading up to PISCES data....likely at ASCO in June.
Volume in Oncosec shares continues to be strong and way above normal. Holding up well in a scary market today.
Volume and price action is undeniably positive in Oncosec!
High volume the last few days in Oncosec stock. Likely some heavy hitters are accumulating stock. We will probably have to wait for next quarters sec filings for Oncosec shareholders to see who has been buying.
Well, you won't have to hear about it much longer....because when Oncosec is bought out there will be nothing more to talk about when either Merck or Bristol Myers takes charge of their pipeline. 2018 is going to be a great year for Oncosec shareholders.
Oncosec is definitely on market radar heading into AACR (TNBC news) and anticipation for PISCES data shortly and most likely at ASCO in June. https://www.bizjournals.com/prnewswire/press_releases/2018/03/26/enUK201803265606